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Background: Serum amyloid A protein (SAA) is both an inflammatory factor and an apolipoprotein. However, the
relation between genetic polymorphisms of SAA and cerebral infarction (CI) remains unclear.
Methods and results: The previously reported 4 Single Nucleotide Polymorphisms (rs12218, rs4638289, rs7131332,
and rs11603089) of SAA1 gene were genotyped by TaqMan method in a case–control study including 287 cerebral
infarction patients and 376 control subjects. We found rs12218 CC genotype and rs7131332 AA genotype were
more frequent among CI patients than among controls (9.76% versus 3.19%, P = 0.001; 32.75% versus 24.20%;
p = 0.017; respectively). After adjustment of confounding factors such as sex, age, smoking, drinking, hypertension,
diabetes, and lipids profile, the difference remained significant in rs12218 (P < 0.01, OR = 2.106, 95% CI: 1.811–7.121).
Conclusion: Genetic polymorphism of SAA1 may be a genetic maker of cerebral infarction in Chinese.
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Stroke is the second leading cause of death throughout
the world, causing more serious chronic disabilities than
any other diseases [1]. Many studies demonstrated that
ischemic stroke including cerebral infarction is a multi-
factor disorder resulting from the interaction between
environmental factor and genetics background [2-5].
Serum amyloid A (SAA) is a sensitive acute phase
proteins in plasma, also SAA is an apolipoprotein that
can replace apolipoprotein A1 (apoA1) as the major
apolipoprotein of high-density lipoprotein (HDL), par-
ticularly during the acute phase response [6]. Recently,
several studies reported the association of SAA1 gen-
etic polymorphism with carotid atherosclerosis [7],
lipids levels [8], Uric acid level [9], and peripheral ar-
terial disease [10]. However, the relationship between
genetic polymorphisms of SAA and cerebral infarction
remains unknown.
In this exploratory study, we investigated the association
between genetic polymorphisms of SAA1 and cerebral in-
farction in a Chinese population.* Correspondence: zhaojianhua_z@126.com
Department of Neurology, First Affiliated Hospital of Xinxiang Medical
College, Xinxiang, Henan 453100, P R. China
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reproduction in any medium, provided the orSubjects and methods
The present study was approved by the Ethics Committee
of the First Affiliated Hospital of Xinxiang Medical College
and was conducted according to the standards of the
Declaration of Helsinki. Written informed consent was
obtained from the participants.
The present study included 287 unrelated adult Chinese
patients with acute hemispheric ischemic stroke and 376
symptom free Chinese controls. Cases were selected among
patients suffering from atherothrombotic ischemic stroke
admitted to the neurology services, within 24 h after onset.
Recruitment of the patients was performed consecutively.
Stroke was defined as clinical designation for a rapidly de-
veloping loss of brain functions that lasted at least 24 h and
had no apparent cause other than that of vascular origin.
The cerebral infarction was initially diagnosed on the basis
of neurological examination and brain computer tomog-
raphy (CT) scan and then transthoracic echocardiographic
examination, Holter study and Transcranial Doppler
emboli detection procedure to rule out emboli source. In
order to be considered eligible, the patients should meet
following criteria: having anterior circulation stroke, no
other major illnesses, including autoimmune diseases,
neoplasms, coagulopathies, hepatic or renal failure, no
known embolic source (aortic arch, cardiac or carotid), no
family history of hematological, autoimmune or chronicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





















Case group 287 61.1 ± 10.4 23.2 ± 3.6 144.6 ± 22.1 89.2 ± 12.4 302.4 ± 130.3 7.1 ± 3.7 3.14 ± 2.11 5.3 ± 2.5 1.9 ± 1.3 2.82 ± 1.42
Control group 376 62.2 ± 10.5 23.9 ± 3.1 126.1 ± 18.4 78.1 ± 11.9 278.3 ± 81.2 5.3 ± 1.6 1.44 ± 1.21 4.7 ± 1.5 1.7 ± 0.9 2.38 ± 1.11
P 0.14 0.33 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.19 0.07
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infarction within 3 weeks.
Control subjects were selected randomly from the
neurology outpatient clinics who did not have stroke or
transient ischemic attack at any time. All exclusion criteria
were applied to the controls exactly plus not having
ischemic heart disease, carotid stenosis (lumen narrowing)
or ulcerated carotid plaque.
Genotyping
Blood samples were collected from all participants, and
genomic DNA was extracted from the peripheral blood
leukocytes by DNA extraction Kit (Beijing Bioteke Co.
Ltd. China). We selected the tagging single-nucleotide
polymorphisms (SNPs) according to the previous studie [9].
Four tagging SNPs (rs12218, rs4638289, rs7131332 and
rs11603089) for Chinese Han were genotyped by TaqMan
method as described previously [11].
Biochemical analysis
Serum and plasma collected for measurement was im-
mediately frozen at - 80°C until analysis. We measured
the plasma concentration of total cholesterol and HDL
cholesterol and the serum concentration of creatinine
and uric acid for all the subjects.
Statistical analyses
Analyses were carried out using SPSS version 17.0 (SPSS,
Chicago, IL, USA). The Hardy–Weinberg equilibrium was
assessed by chi-square analyses. The differences in the dis-
tribution of genotypes between cerebral infarction patients
and control subjects were analyzed using the chi-squareTable 2 Distributions of SAA1 genotypes
SNPs Allels (1/2) Groups n
1/1
rs11603089 A/G Control 376 271 (72.07)
Case 287 199(69.34)
rs4638289 A/T Control 376 150(39.89)
Case 287 112(39.02)
rs12218 C/T Control 376 218(57.98)
Case 287 145(50.52)
rs7131332 A/G Control 376 91(24.20)
Case 287 94 (32.75)test. Logistic regression analyses were used to assess the
contribution of the major risk factors. Two-tailed p -values,
0.05, were considered significant.
Results
Characteristics of study participants
The clinical and metabolic characteristics of the study
population are shown in Table 1.
SAA1 genotype and allele frequencies
All genotyped SNPs were in Hardy-Weinberg equilibrium
in the control group (P > 0.05, data not shown). Table 2
shows detailed information for each SNP as well as the
allele frequencies.
Association of SAA1 gene polymorphisms and CAD
We found rs12218 CC genotype and C allele were more
frequent among cerebral infarction patients than among
controls subjects (9.76% versus 3.19%, P = 0.001; 0.30 versus
0.23, P = 0.004; respectively). For rs7131332, we found
AA genotype was associated with cerebral infarction
(32.75% versus 24.20%, P = 0.017). After adjustment of
confounding factors such as sex, age, smoking, alcohol
consumption, hypertension, diabetes, and lipids levels,
the difference remained significant between the cerebral
infarction patients and the control subjects in rs12218
((P < 0.01, OR = 2.106, 95% CI: 1.811–7.121).
Discussion
In the present study, we found that rs12218 variation in
the SAA1 gene was associated with cerebral infarction in
a Chinese population. To the best of our knowledge, thisGenotypes (n,%) P value MAF P value
1/2 2/2
98(26.06) 7(1.86) 0.610 0.15 0.364
80(27.87) 8(2.79) 0.17
189(50.27) 45(11.97) 0.102 0.37 0.372
155(54.01) 20(6.97) 0.34
146(38.83) 12 (3.19) 0.001 0.23 0.004
114 (39.72) 28(9.76) 0.30
224(59.57) 61(16.22) 0.017 0.46 0.252
140 (48.78) 53(18.47) 0.43
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in SAA1 gene and its association with cerebral infarction
in Chinese population.
SAA1 encodes one important inflammation factor, SAA,
which is also a kind of apolipoprotein [9]. In plasma, SAA
is associated with HDL [7,12,13] and, during severe in-
flammation, can contribute about 80% of its apo-protein
composition [14,15]. Therefore, SAA1 is candidates for
atherosclerosis and cerebral infarction. Recently, Xie et al.
reported that rs12218 polymorphism in SAA1 gene was
associated with IMT [8], HDL-C [9], Ankle-brachial index
(ABI) [10], and plasma Uric acid levels [11] which was
related to cardiovascular and cerebrovascular disease.
In the present study, we performed a case–control study
to observe the relationship between SAA1 genetic poly-
morphism and cerebral infarction. We found rs12218 CC
genotype was very common in the cerebral infarction pa-
tients than that in the control subjects. After adjustment
some confounders, the association remains significant,
which indicated that rs12218 CC genotype was an in-
dependent risk factor for cerebral infarction.
The mechanisms which may link SAA1 genetic poly-
morphism to cerebral infarction are largely unknown.
According to the previous studies, plasma HDL-C and
SAA levels is demonstrated to be associated with SAA
polymorphism, which may be a possible mechanism linking
SAA1 genetic polymorphism to cerebral infarction which
merits further investigation. In addition, the present study
was limited by the relatively small sample size. This may
have led to weak statistical significance and wide CIs when
estimating OR.
In conclusion, the SAA1 genetic polymorphisms were
associated with cerebral infarction in a Chinese population.
Abbreviations
SAA: Serum amyloid A; CI: Cerebral infarction; HDL-C: High-density
lipoprotein; LDL-C: Low-density lipoprotein.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LJZ and BW carried out the molecular genetic studies and drafted the manuscript.
HHL and SBT carried out the genotyping. HQY, LC participated in the design of
the study and performed the statistical analysis. JHZ and LJZ conceived of the
study, and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was funded by the Xinxiang Medical college Science and
Technology Projects (grant number 2007YJAO2).
Received: 26 July 2013 Accepted: 14 August 2013
Published: 29 August 2013
References
1. Peng L, Li P, Chen J, Yan K, Huo F, Han L, Li C, Tan S, Jiang X: Association
between transforming growth factor-beta 1 T869C polymorphism and
ischemic stroke: a meta-analysis. PLoS One 2013, 8:e67738.2. Yao YS, Chang WW, Jin YL, He LP: An updated meta-analysis of endothelial
nitric oxide synthase gene: three well-characterized polymorphisms with
ischemic stroke. Gene 2013. doi:10.1016/j.gene.2013.06.047.
3. Liu X, Zhu R, Li L, Deng S, Li Q, He Z: Genetic polymorphism in PDE4D
gene and risk of ischemic stroke in Chinese population: a meta-analysis.
PLoS One 2013, 8:e66374. doi:10.1371/journal.pone.0066374.
4. Guo L, Zhang LL, Zheng B, Liu Y, Cao XJ, Pi Y, Li BH, Li JC: The C825T
polymorphism of the G-protein β3 subunit gene and its association with
hypertension and stroke: an updated meta-analysis. PLoS One 2013,
8:e65863. doi:10.1371/journal.pone.0065863.
5. Liang B, Qin L, Wei H, Yan Y, Su L, Wu G, Tan J, Gu L: AGT M235T
polymorphisms and ischemic stroke risk: a meta-analysis. J Neurol Sci
2013, 331:118–25. doi:10.1016/j.jns.2013.05.034.
6. Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR, et
al: HDL remodeling during the acute phase response. Arterioscler Thromb
Vasc Biol 2009, 29:261–267.
7. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Huang D, et al: Polymorphisms in the
SAA1/2 gene are associated with carotid intima media thickness in
healthy Han Chinese subjects: the cardiovascular risk survey. PLoS One
2010, 5:e13997. doi:10.1371/journal.pone.0013997.
8. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, et al: Association of genetic
polymorphisms of serum amyloid protein A1 with plasma high density
lipoproteins cholesterol. Zhonghua Yi Xue Za Zhi 2010, 90:1824–6.
9. Xie X, Ma YT, Yang YN, Li XM, Fu ZY, Zheng YY, et al: Serum uric acid levels
are associated with polymorphism in the SAA1 gene in Chinese subjects.
PLoS One 2012, 7:e40263.
10. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Zheng YY, et al: Polymorphisms in the
SAA1 gene are associated with ankle-to-brachial index in Han Chinese
healthy subjects. Blood Press 2011, 20:232–8.
11. Xie X, Ma YT, Fu ZY, Yang YN, Ma X, FU ZY, et al: Haplotype analysis of the
CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb
Hemost 2009, 15:574–580.
12. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA: SAA, an apoprotein
of HDL: its structure and function. Ann N Y Acad Sci 1982, 389:183–189.
13. Clifton PM, Mackinnon AM, Barter PJ: Effects of serum amyloid A protein
(SAA) on composition, size, and density of high density lipoproteins in
subjects with myocardial infarction. J Lipid Res 1985, 26:1389–1398.
14. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, et al:
Serum amyloid A-containing human high density lipoprotein 3: density, size,
and apolipoprotein composition. J Biol Chem 1986, 261:9644–9651.
15. Graversen JH, Castro G, Kandussi A, Nielsen H, Christensen EI, et al: A pivital
role of the human kidney in catabolism of HDL. Protein components
apolipoprotein A-I and A-IV but not of A-II. Lipids 2008, 43:467–470.
doi:10.1186/1476-511X-12-130
Cite this article as: Zhang et al.: Associations of genetic polymorphisms
of SAA1 with cerebral infarction. Lipids in Health and Disease 2013 12:130.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
